Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2011

01.09.2011 | Laboratory Investigation - Human/Animal Tissue

HMGN5: a potential oncogene in gliomas

verfasst von: Jintao Qu, Runmin Yan, Juxiang Chen, Tao Xu, Jingxu Zhou, Mei Wang, Chao Chen, Yong Yan, Yicheng Lu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Gliomas are the most common primary brain tumors in the central nervous system and a leading cause of tumor-related death. High-mobility group nucleosome binding domain 5 (HMGN5/NSBP1), which is highly expressed in breast cancer and in hormone-induced mouse uterine adenocarcinoma, acts as a potential oncogene in gliomas. In this study, the role of HMGN5 in the proliferation of human glioma cells was investigated by lentivirus-mediated RNA interference (RNAi). The decrease in HMGN5 expression in human glioma U251 and U87 cells caused cell cycle arrest in the G1 phase and a delay in cell proliferation, as well as resulting in more apoptosis and an inhibition of clonogenic growth in soft agar in U251 cells; these results suggest that HMGN5 is required for tumorigenesis in vitro. Furthermore, HMGN5 was highly expressed in both high-grade and low-grade glioma tissue samples compared with normal brain tissues. Collectively, our data suggest that HMGN5 may play a critical role in the development of gliomas.
Literatur
1.
Zurück zum Zitat Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3):255–268PubMedCrossRef Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3):255–268PubMedCrossRef
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–96 Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–96
3.
4.
Zurück zum Zitat Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor—mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12(24):7261–7270PubMedCrossRef Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor—mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12(24):7261–7270PubMedCrossRef
5.
Zurück zum Zitat Zhou YH, Hu Y, Mayes D et al (2010) PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. J Neurooncol 96(2):191–200PubMedCrossRef Zhou YH, Hu Y, Mayes D et al (2010) PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. J Neurooncol 96(2):191–200PubMedCrossRef
6.
Zurück zum Zitat Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T (2009) Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res 69(20):7953–7959PubMedCrossRef Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T (2009) Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res 69(20):7953–7959PubMedCrossRef
7.
Zurück zum Zitat Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9):3369–3375PubMed Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9):3369–3375PubMed
8.
Zurück zum Zitat Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20(6):652–661PubMedCrossRef Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20(6):652–661PubMedCrossRef
9.
Zurück zum Zitat Xu T, Chen J, Lu Y, Wolff JE (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252PubMedCrossRef Xu T, Chen J, Lu Y, Wolff JE (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252PubMedCrossRef
10.
Zurück zum Zitat Postnikov Y, Bustin M (2010) Regulation of chromatin structure and function by HMGN proteins. Biochim Biophys Acta 1799(1–2):62–68PubMed Postnikov Y, Bustin M (2010) Regulation of chromatin structure and function by HMGN proteins. Biochim Biophys Acta 1799(1–2):62–68PubMed
11.
Zurück zum Zitat Rochman M, Postnikov Y, Correll S et al (2009) The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol Cell 35(5):642–656PubMedCrossRef Rochman M, Postnikov Y, Correll S et al (2009) The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol Cell 35(5):642–656PubMedCrossRef
12.
Zurück zum Zitat King LM, Francomano CA (2001) Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics 71(2):163–173PubMedCrossRef King LM, Francomano CA (2001) Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics 71(2):163–173PubMedCrossRef
13.
Zurück zum Zitat Rochman M, Malicet C, Bustin M (2010) HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta 1799(1–2):86–92PubMed Rochman M, Malicet C, Bustin M (2010) HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta 1799(1–2):86–92PubMed
14.
Zurück zum Zitat Li DQ, Hou YF, Wu J et al (2006) Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 42(18):3274–3286PubMedCrossRef Li DQ, Hou YF, Wu J et al (2006) Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 42(18):3274–3286PubMedCrossRef
15.
Zurück zum Zitat Tang WY, Newbold R, Mardilovich K et al (2008) Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149(12):5922–5931PubMedCrossRef Tang WY, Newbold R, Mardilovich K et al (2008) Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149(12):5922–5931PubMedCrossRef
Metadaten
Titel
HMGN5: a potential oncogene in gliomas
verfasst von
Jintao Qu
Runmin Yan
Juxiang Chen
Tao Xu
Jingxu Zhou
Mei Wang
Chao Chen
Yong Yan
Yicheng Lu
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-011-0558-9

Weitere Artikel der Ausgabe 3/2011

Journal of Neuro-Oncology 3/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.